Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) (MarketWatch)
Biohaven Pharmaceutical Holding Co. Ltd. BHVN, -12.72% shares dropped nearly 23% in premarket trade Monday after the company released data from two phase 3 clinical trials for its migraine drug rimegepant. The company touted that the drug had met both registrational co-primary endpoints in the two trials, and said it plans to file for approval with the Food and Drug Administration in 2019, but it will also have a formidable rival in this drug category, biopharmaceutical company Allergan AGN, -0.90% Allergan shares rose 1.6% in premarket trade.
Facebook, Inc. (NASDAQ:FB) (Reuters)
WASHINGTON (Reuters) – Facebook Inc (FB.O) shares fell as much as 6.5 percent on Monday after the main U.S. consumer protection regulator said it was investigating how the social network allowed data of 50 million users to get into the hands of a political consultancy. Scrutiny by the U.S. Federal Trade Commission, which generally confirms the existence of an investigation only in cases of significant public interest, adds to pressure from lawmakers in the United States and Europe for Facebook Chief Executive Mark Zuckerberg to explain how his company handles user data. Facebook shares briefly dipped below $150 on Monday for the first time since July 2017, before recouping some losses. They were down 3.1 percent at $154.37 in afternoon trading.
Longfin Corp (NASDAQ:LFIN) (CNBC)
Shares of Longfin, which have spiked astronomically on ties to blockchain technology, fell Monday after a tweet from noted short-selling firm Citron Research. Longfin (Ticker: LFIN) shares briefly tumbled 13.5 percent and were trading 8.9 percent lower near $64.77 as of 11:13 a.m. ET. The tiny, little-known stock surged more than 1,200 percent over two trading days in mid-December after the financial technology company said it is purchasing a firm focused on blockchain, the technology behind cryptocurrencies such as bitcoin.
Verona Pharma PLC – ADR (NASDAQ:VRNA) (Benzinga)
Verona Pharma plc shares jumped 44.4 percent to $23.3999 after the company disclosed positive top-line data from Phase 2b clinical trial of RPL554 for the maintenance treatment of chronic obstructive pulmonary disease.
USG Corporation (NYSE:USG) (Yahoo Finance)
USG Corp (USG): Shares are climbing today, up around 15.9%. Berkshire Hathaway revealed that it proposed selling its approximately 30% stake in the building materials company to Germany’s Knauf group, for $42 a share.
Microsoft Corporation (NASDAQ:MSFT) (CNBC)
“Strong positioning for ramping public cloud adoption, large distribution channels and installed customer base, and improving margins support a path to $50 billion in EBIT and a $1 trillion market cap for MSFT,” Morgan Stanley’s Keith Weiss wrote in a note to clients Monday. The investment bank raised its one-year price target from $110 to $130, 49 percent higher than where the stock closed on Friday. At $130, Microsoft would be worth $1 trillion. Its current market value is $671 billion, behind Apple at $856 billion, Amazon at $747 billion and Alphabet at $730 billion. Shares of Microsoft rose more than 5.5 percent following Morgan Stanley’s call.
DarioHealth Corp (NASDAQ:DRIO) (MarketWatch)
Shares of DarioHealth Corp. DRIO, +22.86% are up 29% in premarket trading Monday after the company said it had received FDA clearance for its blood glucose monitoring system to be used on Apple Inc. AAPL, +3.33% iPhone 7, 8, and X devices via the Lightning port on these phones. The monitor also works with a 3.5mm headphone jack. “With today’s news, DarioHealth plans to expand U.S. sales in the coming weeks,” the company said in a release.
Protagonist Therapeutics Inc (NASDAQ:PTGX) (Benzinga)
Protagonist Therapeutics, Inc. shares tumbled 56.4 percent to $8.90 as the company disclosed that it has discontinued Phase 2b PROPEL trial of PTG-100 for the treatment of ulcerative colitis following interim analysis.
Finish Line Inc (NASDAQ:FINL) (Yahoo Finance)
Finish Line (FINL): Shares soaring in early trade, up around 29%. The athletic retailer agreed to be bought by JD Sports Fashion for $13.50 a share, or $558 million.